“…Icatibant, a bradykinin B(2) receptor antagonist, is also under investigation for treatment of HAE. 34,35 Conclusions HAE is a relatively uncommon disorder that many physicians may rarely, if ever, encounter, but it should be recognized as an important and potentially life-threatening condition. Significant progress has been made since the first description of a hereditary form of AE in the late 1800s, and our understanding of the underlying pathology has led, in recent years, to more specific and better-tolerated treatments.…”